scholarly journals Role of cytochrome P450 2C8 genetic polymorphism and epoxygenase uncoupling in periodontal remodeling affecting orthodontic treatment

Author(s):  
Sabrina Yamoune ◽  
Katharina Wintz ◽  
Christian Niederau ◽  
Rogerio B. Craveiro ◽  
Michael Wolf ◽  
...  
2009 ◽  
Vol 29 (1) ◽  
pp. 32-43 ◽  
Author(s):  
Lu Sun ◽  
Zhong-Hua Wang ◽  
Feng-Yun Ni ◽  
Xiang-Shi Tan ◽  
Zhong-Xian Huang

2008 ◽  
Vol 18 (11) ◽  
pp. 943-953 ◽  
Author(s):  
Helen E. Smith ◽  
J.P. Jones ◽  
Thomas F. Kalhorn ◽  
Federico M. Farin ◽  
Patricia L. Stapleton ◽  
...  

Author(s):  
Smriti Mishra ◽  
Manish Manish

<p><span>The role of pharmacogenetics in the personalization of tamoxifen therapy has relevance in the management of breast cancer. Since Tamoxifen is a pro-drug, genetic polymorphism in Phase I and Phase II drug metabolizing enzymes involved in the bioconversion of tamoxifen to therapeutically active metabolites is critical in determining therapeutic efficacy and adverse drug reactions of the therapy in breast cancer patients. In this review, the role of pharmacogenetics in the personalization of tamoxifen therapy has been discussed. Since, metabolism of tamoxifen by Cytochrome P450 2D6 is significant in determining the therapeutic efficacy of the drug, most of the clinical evidence on tamoxifen pharmacogenetics have been correlated with cytochrome p450 2D6 genetic polymorphism. However, there is discordance in the clinical data, and one of the reasons is the incomplete analysis of all the alleles of cytochrome p450 2D6. International Tamoxifen Pharmacogenomics Consortium has been formed to assess   the discordance. There are also clinical evidences associating genetic polymorphism in cytochrome P450 3A, 2C9, 2C19, Uridine diphosphate –glucuronosyltransferases and Sulfotransferases with clinical outcome of tamoxifen therapy. However, associations of genetic polymorphism in cytochrome P450 3A, 2C9, 2C19, Uridine diphosphate –glucuronosyltransferases and Sulfotransferases with clinical outcome in populations of different ethnicity are unexplored. Evidences on  the association of genetic polymorphisms and the clinical outcome have been summarized in the Table.  Since cost, statistically significant sample population size, labor and ethical issues are the major concerns of a pharmacogenetic investigation; the significance of bottom-up approach in pharmacogenetics has been discussed.</span></p>


2016 ◽  
pp. 1909 ◽  
Author(s):  
Zhe Wang ◽  
Li Wang ◽  
Ren-ai Xu ◽  
Yun-yun Zhan ◽  
Cheng-ke Huang ◽  
...  

2019 ◽  
Vol 29 ◽  
pp. S454-S455
Author(s):  
R. Zakharyan ◽  
V. Hayrapetyan ◽  
L. Karapetyan ◽  
A. Chavushyan ◽  
A. Arakelyan

2015 ◽  
Vol 68 (1) ◽  
pp. 168-241 ◽  
Author(s):  
Janne T. Backman ◽  
Anne M. Filppula ◽  
Mikko Niemi ◽  
Pertti J. Neuvonen

2008 ◽  
Vol 41 (05) ◽  
Author(s):  
E Jaquenoud-Sirot ◽  
B Knezevic ◽  
G Perla Morena ◽  
P Baumann ◽  
CB Eap

Author(s):  
Lyudmila P. Kuzmina ◽  
Anastasiya G. Khotuleva ◽  
Evgeniy V. Kovalevsky ◽  
Nikolay N. Anokhin ◽  
Iraklij M. Tskhomariya

Introduction. Various industries widely use chrysotile asbestos, which determines the relevance of research aimed at the prevention of asbestos-related diseases. It is promising to assess the role of specific genes, which products are potentially involved in the development and regulation of certain links in the pathogenesis of asbestosis, forming a genetic predisposition to the disease. The study aims to analyze the presence of associations of genetic polymorphism of cytokines and antioxidant enzymes with asbestosis development. Materials and methods. Groups were formed for examination among employees of OJSC "Uralasbest" with an established diagnosis of asbestosis and without lung diseases. For each person included in the study, dust exposure doses were calculated considering the percentage of time spent at the workplace during the shift for the entire work time. Genotyping of single nucleotide polymorphisms of cytokines IL1b (rs16944), IL4 (rs2243250), IL6 (rs1800795), TNFα (rs1800629) and antioxidant enzymes SOD2 (rs4880), GSTP1 (rs1610011), CAT (rs1001179) was carried out. Results. The authors revealed the associations of polymorphic variants A511G IL1b gene (OR=2.457, 95% CI=1.232-4.899) and C47T SOD2 gene (OR=1.705, 95% CI=1.055-2.756) with the development of asbestosis. There was an increase in the T allele IL4 gene (C589T) frequency in persons with asbestosis at lower values of dust exposure doses (OR=2.185, 95% CI=1.057-4.514). The study showed the associations of polymorphism C589T IL4 gene and C174G IL6 gene with more severe asbestosis, polymorphism A313G GSTP1 gene with pleural lesions in asbestosis. Conclusion. Polymorphic variants of the genes of cytokines and antioxidant enzymes, the protein products directly involved in the pathogenetic mechanisms of the formation of asbestosis, contribute to forming a genetic predisposition to the development and severe course of asbestosis. Using the identified genetic markers to identify risk groups for the development and intense period of asbestos-related pathology will optimize treatment and preventive measures, considering the organism's characteristics.


Sign in / Sign up

Export Citation Format

Share Document